Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.36
HAE's Cash to Debt is ranked lower than
73% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. HAE: 0.36 )
Ranked among companies with meaningful Cash to Debt only.
HAE' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.96 Max: 60.69
Current: 0.36
0.09
60.69
Equity to Asset 0.56
HAE's Equity to Asset is ranked lower than
53% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. HAE: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
HAE' s Equity to Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.65 Max: 0.84
Current: 0.56
0.52
0.84
F-Score: 4
Z-Score: 3.30
M-Score: -3.16
WACC vs ROIC
8.65%
-4.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -5.50
HAE's Operating margin (%) is ranked lower than
65% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.66 vs. HAE: -5.50 )
Ranked among companies with meaningful Operating margin (%) only.
HAE' s Operating margin (%) Range Over the Past 10 Years
Min: -5.5  Med: 12.55 Max: 16.34
Current: -5.5
-5.5
16.34
Net-margin (%) -6.48
HAE's Net-margin (%) is ranked lower than
63% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.06 vs. HAE: -6.48 )
Ranked among companies with meaningful Net-margin (%) only.
HAE' s Net-margin (%) Range Over the Past 10 Years
Min: -6.48  Med: 9.12 Max: 11.82
Current: -6.48
-6.48
11.82
ROE (%) -7.97
HAE's ROE (%) is ranked lower than
66% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. HAE: -7.97 )
Ranked among companies with meaningful ROE (%) only.
HAE' s ROE (%) Range Over the Past 10 Years
Min: -7.97  Med: 9.87 Max: 12.5
Current: -7.97
-7.97
12.5
ROA (%) -4.36
HAE's ROA (%) is ranked lower than
62% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. HAE: -4.36 )
Ranked among companies with meaningful ROA (%) only.
HAE' s ROA (%) Range Over the Past 10 Years
Min: -4.36  Med: 7.98 Max: 10.03
Current: -4.36
-4.36
10.03
ROC (Joel Greenblatt) (%) -8.65
HAE's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. HAE: -8.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HAE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8.65  Med: 28.98 Max: 38.15
Current: -8.65
-8.65
38.15
Revenue Growth (3Y)(%) 1.50
HAE's Revenue Growth (3Y)(%) is ranked lower than
60% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. HAE: 1.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HAE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.4  Med: 7.4 Max: 15
Current: 1.5
-1.4
15
EBITDA Growth (3Y)(%) -27.10
HAE's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. HAE: -27.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HAE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.1  Med: 5 Max: 105.5
Current: -27.1
-27.1
105.5
GuruFocus has detected 5 Warning Signs with Haemonetics Corp $HAE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HAE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HAE Guru Trades in Q1 2016

Jim Simons 277,200 sh (+46.13%)
Ken Fisher 219,127 sh (+0.01%)
Barrow, Hanley, Mewhinney & Strauss Sold Out
» More
Q2 2016

HAE Guru Trades in Q2 2016

Joel Greenblatt 39,575 sh (New)
Paul Tudor Jones 16,898 sh (New)
Jim Simons 777,300 sh (+180.41%)
Ken Fisher 257,467 sh (+17.50%)
» More
Q3 2016

HAE Guru Trades in Q3 2016

Steven Cohen 685,800 sh (New)
Jim Simons 883,600 sh (+13.68%)
Ken Fisher 267,712 sh (+3.98%)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2016

HAE Guru Trades in Q4 2016

Ken Fisher 267,667 sh (-0.02%)
» More
» Details

Insider Trades

Latest Guru Trades with HAE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ICUI, NYSE:HYH, NAS:NXTM, NAS:PODD, OTCPK:TOPCF, OTCPK:ANSLY, NYSE:GKOS, NAS:MMSI, NYSE:CMD, NAS:LMNX, NAS:ATRI, NAS:IRTC, NAS:ANGO, OTCPK:NNCSF, NAS:NVCR, NAS:ELGX, NAS:ATRC, NAS:OSUR, NAS:LMAT, NAS:MLAB » details
Traded in other countries:HAZ.Germany,
Haemonetics Corp is a healthcare company that provides blood management solutions to its customers. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals.

Haemonetics Corp is a Massachusetts corporation founded in 1971. It is a healthcare company that provides blood management solutions to its customers. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helps improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world. The company provide plasma collection systems and software which enable plasma fractionators to make pharmaceuticals and analytical devices for measuring hemostasis. It also makes blood processing systems and softwares for blood donation. Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals. Its product categories include: Plasma, Blood Center, Hospital, and Software Solutions. Plasma includes manufacture and market plasma collection devices and disposables. Blood Center includes automated blood component and manual whole blood collection systems to blood collection centers. Hospital : Loss of blood is common in many surgical procedures, including open heart, trauma, transplant, vascular, and orthopedic procedures, and the need for transfusion of oxygen-carrying red cells to make up for lost blood volume is necessary. Haemonetics offers a range of blood management solutions that improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing efficiently and perfectly. It also includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions: The company has a suite of integrated software solutions for improving efficiencies and helping ensure donor and patient safety. This includes solutions for blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution, transfusion management, and remote blood allocation. The company market and sell their products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations through their own direct sales force (including full-time sales representatives and clinical specialists) as well as independent distributors. The Company's competitors include Terumo BCT, Sorin Biomedica and Fresenius SE & Co. KGaA. The products it manufactures and markets are subject to regulation by the Center of Biologics Evaluation and Research and the Center of Devices and Radiological Health of the United States Food and Drug Administration, and other non-United States regulatory bodies.

Top Ranked Articles about Haemonetics Corp

Weekly CEO Buys Highlights Insiders invest in Penske Automotive, Haemonetics, Gogo, Hanesbrands
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
Forward P/E 23.64
HAE's Forward P/E is ranked lower than
62% of the 37 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.27 vs. HAE: 23.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.78
HAE's P/B is ranked higher than
56% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. HAE: 2.78 )
Ranked among companies with meaningful P/B only.
HAE' s P/B Range Over the Past 10 Years
Min: 1.84  Med: 2.53 Max: 3.4
Current: 2.78
1.84
3.4
P/S 2.28
HAE's P/S is ranked higher than
57% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. HAE: 2.28 )
Ranked among companies with meaningful P/S only.
HAE' s P/S Range Over the Past 10 Years
Min: 1.47  Med: 2.36 Max: 3.59
Current: 2.28
1.47
3.59
PFCF 33.85
HAE's PFCF is ranked lower than
64% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.12 vs. HAE: 33.85 )
Ranked among companies with meaningful PFCF only.
HAE' s PFCF Range Over the Past 10 Years
Min: 15.75  Med: 33.96 Max: 486.52
Current: 33.85
15.75
486.52
POCF 13.34
HAE's POCF is ranked higher than
67% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.81 vs. HAE: 13.34 )
Ranked among companies with meaningful POCF only.
HAE' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 14.41 Max: 25.67
Current: 13.34
9.91
25.67
EV-to-EBITDA 57.99
HAE's EV-to-EBITDA is ranked lower than
89% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.68 vs. HAE: 57.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
HAE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.1  Med: 12.2 Max: 61.4
Current: 57.99
7.1
61.4
Shiller P/E 48.23
HAE's Shiller P/E is ranked lower than
57% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.08 vs. HAE: 48.23 )
Ranked among companies with meaningful Shiller P/E only.
HAE' s Shiller P/E Range Over the Past 10 Years
Min: 25.71  Med: 34.96 Max: 51.8
Current: 48.23
25.71
51.8
Current Ratio 2.58
HAE's Current Ratio is ranked higher than
54% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.44 vs. HAE: 2.58 )
Ranked among companies with meaningful Current Ratio only.
HAE' s Current Ratio Range Over the Past 10 Years
Min: 2.17  Med: 3.24 Max: 4.92
Current: 2.58
2.17
4.92
Quick Ratio 1.60
HAE's Quick Ratio is ranked lower than
51% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. HAE: 1.60 )
Ranked among companies with meaningful Quick Ratio only.
HAE' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.28 Max: 4.22
Current: 1.6
1.51
4.22
Days Inventory 139.93
HAE's Days Inventory is ranked lower than
59% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.20 vs. HAE: 139.93 )
Ranked among companies with meaningful Days Inventory only.
HAE' s Days Inventory Range Over the Past 10 Years
Min: 89.4  Med: 99.05 Max: 156.73
Current: 139.93
89.4
156.73
Days Sales Outstanding 61.08
HAE's Days Sales Outstanding is ranked higher than
55% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.71 vs. HAE: 61.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
HAE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.47  Med: 68.26 Max: 84.99
Current: 61.08
58.47
84.99
Days Payable 29.92
HAE's Days Payable is ranked lower than
81% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.06 vs. HAE: 29.92 )
Ranked among companies with meaningful Days Payable only.
HAE' s Days Payable Range Over the Past 10 Years
Min: 26.02  Med: 31.36 Max: 41.58
Current: 29.92
26.02
41.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
HAE's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. HAE: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HAE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.7  Med: 0.6 Max: 1.9
Current: 0.1
-3.7
1.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.16
HAE's Price/Tangible Book is ranked lower than
68% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. HAE: 7.16 )
Ranked among companies with meaningful Price/Tangible Book only.
HAE' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.69  Med: 3.42 Max: 13.8
Current: 7.16
1.69
13.8
Price/Projected FCF 2.04
HAE's Price/Projected FCF is ranked lower than
55% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. HAE: 2.04 )
Ranked among companies with meaningful Price/Projected FCF only.
HAE' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.1  Med: 1.56 Max: 2.56
Current: 2.04
1.1
2.56
Price/Median PS Value 0.96
HAE's Price/Median PS Value is ranked higher than
66% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.09 vs. HAE: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
HAE' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 0.98 Max: 1.46
Current: 0.96
0.53
1.46
Earnings Yield (Greenblatt) (%) -2.07
HAE's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. HAE: -2.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HAE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.14  Med: 6 Max: 11.2
Current: -2.07
-2.14
11.2
Forward Rate of Return (Yacktman) (%) -16.05
HAE's Forward Rate of Return (Yacktman) (%) is ranked lower than
91% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.15 vs. HAE: -16.05 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HAE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -16.1  Med: 8.9 Max: 17.8
Current: -16.05
-16.1
17.8

More Statistics

Revenue (TTM) (Mil) $905.9
EPS (TTM) $ -1.16
Beta1.07
Short Percentage of Float3.56%
52-Week Range $25.98 - 41.41
Shares Outstanding (Mil)51.66

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 872 891
EPS ($) 1.57 1.67
EPS w/o NRI ($) 1.57 1.67
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
Dividends Per Share ($)
» More Articles for HAE

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Aug 15 2016 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Meridian Contrarian Fund Second Quarter Commentary Sep 08 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders Jul 22 2014 
This Blood Management Company Can Be A Safe Investment Jul 13 2014 
Meridian Funds Comments on Haemonetics Aug 28 2013 
Meridian Funds' Second Quarter 2013 Commentary Aug 28 2013 
Weeky CFO Sells Highlight: ADBE, HAE, WAGE, OVTI, ICPT Jun 24 2013 
Allscripts-Misys Reports 5 Insider Buys the Day Before Barclays Conference Mar 13 2013 

More From Other Websites
Haemonetics Corp. – Value Analysis (NYSE:HAE) : January 19, 2017 Jan 19 2017
Haemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : January 18, 2017 Jan 18 2017
Haemonetics Sets Date for 3rd Quarter Fiscal 2017 Earnings Release: February 6, 2017 Jan 17 2017
Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View Jan 05 2017
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite Jan 05 2017
Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging Jan 05 2017
ResMed Achieves Key Milestone in Sleep-Disordered Breathing Jan 05 2017
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay Jan 04 2017
Haemonetics to Present at 35th Annual J.P. Morgan Health Care Conference Jan 03 2017
Illumina Fettered With Losses: Can It Bounce Back in 2017? Jan 03 2017
Masimo to Launch Advanced Monitoring Technologies in India Jan 03 2017
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3 Jan 02 2017
Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold? Jan 02 2017
Is Baxter Poised to Counter Low Cyclophosphamide Sales? Dec 30 2016
CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions Dec 30 2016
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege Dec 30 2016
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite Dec 30 2016
LabCorp: Covance Drug Prospects Bright, Competition Rife Dec 29 2016
ResMed: SDB Business Faces Risks, Reimbursement a Drag Dec 29 2016
Nutrisystem Declares Multi-Brand Marketing Approach for '17 Dec 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)